Armenia grants first marketing authorization for Agenus Bot+Bal
Armenia granted marketing authorizations for Agenus’ Bot+Bal in previously treated MSS metastatic colorectal cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Armenia grants first marketing authorizations for Agenus’ BOT+BAL in previously treated MSS metastatic colorectal
Armenia grants marketing authorizations for Agenus BOT+BAL
Agenus said Armenia’s Ministry of Health granted marketing authorizations for Botvymo (botensilimab, BOT) and Evamplix (balstilimab, BAL) for use together in previously treated metastatic colorectal cancer.